Irritable bowel syndrome study

A Phase III study with BEKINDA 24 mg for acute gastroenteritis and gastritis is ongoing in the US

Pharmaceutical enteric film coatings

Kollicoat MAE 100-55 can directly replace comparable pH >5.5 enteric release materials in commercial formulations

3D fluidics printer

Suitable for a wide range of applications, including organ-on-a-chip, point-of-care diagnostics, drug development

Dilated cardiomyopathy

Using induced pluripotent stem cells to study molecular mechanisms in

Treating skin infections

Motif Bio announces the dosing of the first patient in two Phase 3 clinical trials of its lead antibiotic candidate iclaprim

Novel protein biomarkers in prostate cancer identified

Potential drug targets supporting novel strategies in precision medicine

Tackling growing resistance to antibiotics

Loughborough University secures funding to help fight the global health threat of antimicrobial resistance

Chemists recruit anthrax to deliver cancer drugs

With some tinkering, a deadly protein becomes an efficient carrier for antibody drugs

Positive results for PMDD study

Umecrine Mood announces positive results from study with UC1010 in PMDD

Understanding of predictive models in oncology

Industry leaders will discuss use of Patient-Derived Xenograft models to help accelerate oncology drug discovery

Drug Discovery 2014

ELRIG Announces Drug Discovery 2014 Programme and Pre-Conference SLAS Short Courses

Encouraging findings for Parkinson’s disease vaccine

First clinical data of therapeutic Parkinson’s disease vaccine encourages continued development

Securing performance in drug delivery devices

Polymers in Drug Delivery Devices 2014 conference takes place September 16-17 at the Hilton Philadelphia City Avenue in Philadelphia, PA, USA

Silver lining found for making new drugs

Chemical to aid drug manufacturing processes, making it more environmentally-friendly and easier to scale up for industry

High payload targeted drug delivery

New targeted nanoparticles are expected to dramatically improve the effectiveness of both diagnosis and treatment of diseases and reduce dangerous or unpleasant side effects

Anti-vWF nanobody, caplacizumab, achieves proof-of-concept

Phase II TITAN study produces positive results for Abylnx’s anti-vWF nanobody

Novel strategies for combining drug therapy with irradiation

Could deliver new hope for overcoming resistance to oncology therapeutics

Oral agent normalises glucose tolerance and insulin sensitivity

Imeglimin induces glucose-stimulated insulin secretion by improving beta cell glucose sensitivity in Type 2 diabetic patients

New screening library designed to increase hit probability

Delivering highly diverse coverage of drug-like chemical space in a single library

Additional data on ALX-0061 nanobody to be presented

Ablynx will present additional data on ALX-0061, the anti-IL-6R nanobody, at rheumatology congress




To receive the Scientist Live weekly email NewsBrief please enter your details below

Twitter Icon © Setform Limited